Table 2 provides an overview of the main clinical and biological characteristics of approved and investigational FLT3 inhibitors, illustrating the steady refinement of FLT3-directed therapy from early multikinase inhibitors to highly selective agents with defined roles across different stages of AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.